Two muscular-disease programs reported encouraging clinical and safety data this week. Regenxbio disclosed a clean safety profile and functional improvements for its Duchenne muscular dystrophy (DMD) gene therapy as the company prepares for pivotal data readouts. Separately, BridgeBio announced statistically significant Phase 3 efficacy for its muscle‑weakness candidate BBP‑418 ahead of an FDA filing. Both companies emphasized safety and functional endpoints in their releases; Regenxbio highlighted tolerability across dosing cohorts, while BridgeBio focused on the magnitude of effect and its regulatory timing. The results renew attention on genetic and molecular approaches for inherited and acquired muscle disorders.